Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
73.28
-0.54 (-0.74%)
At close: Jun 12, 2026, 4:00 PM EDT
73.75
+0.47 (0.65%)
After-hours: Jun 12, 2026, 6:39 PM EDT
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $246.09M in the quarter ending March 31, 2026, with 86.98% growth. This brings the company's revenue in the last twelve months to $1.06B, up 47.53% year-over-year. In the year 2025, Ionis Pharmaceuticals had annual revenue of $943.71M with 33.83% growth.
Revenue (ttm)
$1.06B
Revenue Growth
+47.53%
P/S Ratio
11.44
Revenue / Employee
$754,772
Employees
1,402
Market Cap
12.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 943.71M | 238.57M | 33.83% |
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
| Dec 31, 2018 | 599.67M | 85.50M | 16.63% |
| Dec 31, 2017 | 514.18M | 141.40M | 37.93% |
| Dec 31, 2016 | 372.78M | 89.07M | 31.40% |
| Dec 31, 2015 | 283.70M | 69.54M | 32.47% |
| Dec 31, 2014 | 214.16M | 66.88M | 45.41% |
| Dec 31, 2013 | 147.29M | 45.24M | 44.33% |
| Dec 31, 2012 | 102.05M | 2.96M | 2.99% |
| Dec 31, 2011 | 99.09M | -9.39M | -8.65% |
| Dec 31, 2010 | 108.47M | -13.13M | -10.80% |
| Dec 31, 2009 | 121.60M | 14.41M | 13.44% |
| Dec 31, 2008 | 107.19M | 48.85M | 83.72% |
| Dec 31, 2007 | 58.34M | 43.49M | 292.65% |
| Dec 31, 2006 | 14.86M | -13.48M | -47.57% |
| Dec 31, 2005 | 28.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ascendis Pharma | 998.25M |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
IONS News
- 2 days ago - Ionis Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 days ago - Ionis Pharmaceuticals appoints Hantson to Board of Directors - TheFly
- 4 days ago - Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors - Business Wire
- 8 days ago - Ionis Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 8 days ago - Ionis Pharmaceuticals Slides: FY 2026 - Filings
- 8 days ago - Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses - Business Wire
- 15 days ago - Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint - TheFly
- 15 days ago - Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B - Business Wire